Table 2.
Risk of hypoglycemia following initiation of SGLT2 inhibitors
| n | Events | Events per 100 person-years (95% CI) | |
| All patients | 171 622 | 216 | 0.60 (0.45 to 0.81) |
| Sex | |||
| Male | 112 521 | 152 | 0.66 (0.47 to 0.94) |
| Female | 59 101 | 64 | 0.47 (0.28 to 0.84) |
| Age (years) | |||
| <25 | 884 | 1 | 0.42 (0.06 to 2.96) |
| 25–44 | 17 136 | 10 | 0.35 (0.10 to 1.29) |
| 45–64 | 69 543 | 53 | 0.38 (0.21 to 0.69) |
| ≥65 | 84 059 | 152 | 0.85 (0.60 to 1.21) |
| BMI (kg/m2) | |||
| <25 | 65 255 | 114 | 1.04 (0.72 to 1.51) |
| ≥25 | 106 365 | 102 | 0.51 (0.32 to 0.82) |
| Antidiabetic medications (n) | |||
| <5 | 155 152 | 186 | 0.61 (0.45 to 0.82) |
| ≥5 | 16 254 | 30 | 0.21 (0.15 to 0.30) |
| Baseline use of antidiabetic medications | |||
| α-GI | 20 283 | 35 | 0.69 (0.35 to 1.67) |
| DPP-4 inhibitors | 97 717 | 119 | 0.61 (0.41 to 0.91) |
| Glinides | 10 290 | 14 | 0.18 (0.15 to 0.23) |
| GLP-1 receptor agonists | 7901 | 8 | 0.19 (0.07 to 0.51) |
| Insulin | 34 915 | 97 | 1.20 (0.80 to 1.88) |
| Metformin | 73 083 | 52 | 0.31 (0.18 to 0.59) |
| Sulfonylureas | 34 903 | 50 | 0.73 (0.39 to 1.40) |
| Thiazolidinediones | 12 996 | 15 | 0.18 (0.15 to 0.23) |
BMI, body mass index; DPP-4, dipeptidyl peptidase-4; α-GI, alpha-glucosidase inhibitor; GLP-1, glucagon-like peptide-1; SGLT2, sodium-glucose cotransporter 2.